ValuEngine lowered shares of Verastem, Inc. (NASDAQ:VSTM) from a hold rating to a sell rating in a report released on Friday, September 1st.
Several other research firms have also issued reports on VSTM. Zacks Investment Research upgraded Verastem from a hold rating to a buy rating and set a $3.75 target price on the stock in a report on Thursday, July 13th. Cann reiterated a buy rating and set a $6.00 target price on shares of Verastem in a report on Tuesday, July 25th. HC Wainwright set a $7.00 price objective on Verastem and gave the company a buy rating in a research note on Thursday, August 10th. Cantor Fitzgerald restated a hold rating and issued a $2.00 price objective on shares of Verastem in a research note on Thursday, May 11th. Finally, Oppenheimer Holdings, Inc. set a $6.00 price objective on Verastem and gave the company a buy rating in a research note on Wednesday, May 10th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of $5.04.
Shares of Verastem (NASDAQ:VSTM) traded up 0.74% on Friday, reaching $5.41. 2,056,124 shares of the company traded hands. Verastem has a 52-week low of $1.05 and a 52-week high of $5.71. The firm has a 50-day moving average of $3.88 and a 200-day moving average of $2.63. The company’s market capitalization is $200.13 million.
Verastem (NASDAQ:VSTM) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.02). On average, equities research analysts forecast that Verastem will post ($1.38) earnings per share for the current fiscal year.
WARNING: “Verastem, Inc. (NASDAQ:VSTM) Rating Lowered to Sell at ValuEngine” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://ledgergazette.com/2017/09/16/verastem-inc-vstm-rating-lowered-to-sell-at-valuengine.html.
A number of large investors have recently modified their holdings of VSTM. TFS Capital LLC acquired a new stake in Verastem during the first quarter worth approximately $113,000. Renaissance Technologies LLC grew its position in Verastem by 20.0% during the first quarter. Renaissance Technologies LLC now owns 1,226,600 shares of the biopharmaceutical company’s stock worth $2,539,000 after buying an additional 204,400 shares in the last quarter. Howland Capital Management LLC grew its position in Verastem by 16.5% during the second quarter. Howland Capital Management LLC now owns 294,007 shares of the biopharmaceutical company’s stock worth $641,000 after buying an additional 41,616 shares in the last quarter. Alpine Woods Capital Investors LLC acquired a new stake in Verastem during the second quarter worth approximately $109,000. Finally, Artal Group S.A. acquired a new stake in Verastem during the second quarter worth approximately $1,090,000. 24.19% of the stock is currently owned by institutional investors and hedge funds.
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Verastem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.